CYTK Q4 2022 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-96.5% YoY

Gross Profit

-$73M-3733.3% margin

Operating Income

-$127M-6491.1% margin

Net Income

-$137M-7019.9% margin

EPS (Diluted)

$-1.39

QoQ Revenue Growth

-22.2%

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$101M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$1.1B

Stockholders' Equity

-$108M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$56M	-96.5%
Gross Profit	-$73M	$12M	-703.7%
Operating Income	-$127M	-$22M	-485.3%
Net Income	-$137M	-$31M	-349.4%

Revenue Segments

Research And Development

$2M100%